Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants

Crohn's Disease Clinical Trial

— ADACAL  

Official title:

cAlprotectin and hsCRP as Markers of a New Diagnostic-therapeutic strAtegy That Assesses muCosal Activity to individuaLize Treatment and Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01562951
• Other study ID #: A12-771
• Status: Terminated
• Phase: Phase 3
• First received: March 13, 2012
• Last updated: May 3, 2016
• Start date: October 2012
• Est. completion date: March 2014

Study information

• Verified date: May 2016
• Source: Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
• Contact: n/a
• Is FDA regulated: No
• Health authority: Spain: Agencia Española de Medicamentos y Productos SanitariosBelgium: Federal Agency for Medicinal Products and Health ProductsFrance: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
• Study type: Interventional

Clinical Trial Summary

This study will test that individualized treatment in patients with Crohn's Disease in remission or mild clinical activity under immunosuppressants may improve prognosis, rather than just treating flares.

Description:

Patients will be prescreened for inclusion criteria one week before the start of screening at Visit 0 (Prescreening Visit). Patients must be on stable doses of azathioprine/mercaptopurine. Patients will be given a diary to record their CD symptoms for the seven days prior to Visit 1. At Visit 1 (Screening Visit 1), patients will have their CDAI score assessed based upon their diary information. Patients with CDAI ≤ 220 will then have both calprotectin and hsCRP testing done. Patients with calprotectin > or = 250µg/g and/or hsCRP > or = 5mg/L will be notified and told to schedule Visit 2 within three weeks. At Visit 2 (Screening Visit 2), patients will undergo a colonoscopy. A Crohn's Disease Endoscopic Index of Severity (CDEIS) will be used to determine the endoscopic activity. Patients with significant endoscopic lesions will be notified and asked to enroll in the study.

Patients will be randomized into the study at Visit 3 (Randomization Visit, same day of Visit 2 in results available). Due to the cost and invasiveness of the colonoscopy, the Screening Visit 2 colonoscopy will serve as the baseline for the study, should the patient be enrolled. Drug will also be dispensed at this visit. Eligible patients will be randomized in a 1:1 ratio to receive either adalimumab or placebo during the treatment period, along with continuing their current immunosuppressive maintenance treatment at a stable dose. Treatment in both arms will be induction at 160/80mg and maintenance on 40 mg every other week.

Patients will return for follow up visits every 12 weeks until the final follow-up visit at 48 weeks (Visit 7), where another colonoscopy will be performed. Patients who terminate early from the study for any reason will be asked to return for a follow-up visit, where Visit 7 procedures will be performed.

Before week 48, if a patient has an increase of more than 50% in either calprotectin and/or hsCRP over baseline and above the thresholds at any regular visit, a follow-up visit will be performed two weeks later. If the 50% increase is still observed another colonoscopy will be performed, within two weeks of the follow-up visit. If patients still have significant endoscopic lesions, study product will be intensified to 40 mg weekly. This will include patients on placebo in order to preserve the double-blind aspect of the study.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 15
• Est. completion date: March 2014
• Est. primary completion date: March 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age 18-75 years old- Patients with CD diagnosis confirmed by colonoscopy

• Patients with inflammatory CD of terminal ileal, colonic or ileocolonic location

• Maintenance treatment with at least 2 mg/kg/day for azathioprine/ 1 mg/kg/day for mercaptopurine or the highest dosage tolerated in patients who could not tolerate this dosage, at least 6 months.

• Willingness to sign informed consent

• If female of childbearing age, be post-menopausal, surgically sterile, or willing to use a reliable form of birth control for the duration of the study (such as physical barrier [patient and partner], contraceptive pill or patch, spermicide and barrier, or intrauterine device)and for at least five months after the last adalimumab treatment.

• Able to comply with the requirements of the study.

• CDAI score = 220.

• Calprotectin > or = 250µg/g and/or hsCRP > or = 5mg/L.

• Significant lesions seen during colonoscopy, as defined by CDEIS.

Exclusion Criteria:

• Patients with an ostomy, or ileoanal pouch (subject with previous ileo-rectal anastomosis are not excluded), draining fistula, abscess

• Patients who had intestinal resection within one year.

• Symptomatic stricture either diagnosed by colonoscopy or clinically suspected and confirmed by imaging techniques.

• Prior treatment with any anti-tumor necrosis factor (TNF) drug.

• Patients receiving rectal treatment 1 month before inclusion

• Signs of active infection

• Previous history of active untreated or inadequately treated tuberculosis (TB) or latent TB. Patients should be screened for latent TB as per local guidelines or clinical practice in the country of study conduct. Patients with latent TB should be treated with standard antimycobacterial therapy (for at least 4 weeks) before initiating biologic therapy and have a negative CRX for active TB at screening

• Subjects with a poorly controlled medical condition such as: uncontrolled diabetes with documented history of recurrent infections, unstable ischemic heart disease, moderate to severe congestive heart failure (New York Heart Association [NYHA] class III or IV), recent cerebrovascular accident, or any other condition which, in the opinion of the Investigator or the sponsor, would put the subject at risk by participation in the protocol

• Signs of colon cancer or dysplasia

• Signs of severe or unstable renal, hepatic, gastrointestinal, cardiovascular, respiratory, neurological, psychiatric, or hematological disease

• Signs of cancer in the past five years, except for localized and treated basal cell skin cancer or cervical cancer

• Patients who are pregnant or nursing

• Concomitant treatment with:

• Live vaccines.

• 5-ASA compounds: Rectal 5-ASA should be discontinued at least 4 weeks before study inclusion. Oral 5-ASA must be at a stable dose for at least 4 weeks before study inclusion. If oral 5-ASA has recently been discontinued, 4 weeks should pass before study inclusion.

• Oral corticosteroids (eg., Prednisone, budesonide) should be discontinued for 3 months before study inclusion.

• Antibiotics for CD. Only antibiotics used to treat a concurrent infection are allowed.

• Immunomodulators:

Patients receiving therapy with azathioprine/mercaptopurine must have been on a stable dose for at least 12 weeks before inclusion and must continue with the same dose during the study.

No treatment with other known immunomodulators (eg. methotrexate, 6-thioguanine [6-TG], cyclosporine, tacrolimus, sirolimus, ustekinumab, pentoxifylline, or mycophenolate mofetil) or experimental drugs (eg., factor colony stimulating granulocyte macrophage [GM-CSF]) within 6 months

• Monoclonal antibodies or anti-TNF drugs.

• Aspirin or Non-steroidal anti-inflammatory drugs (NSAIDs). Treatment with aspirin and/or NSAIDS should not occur for more than 15 consecutive days before collecting of the stool sample for Calprotectin and performing the colonoscopy.

• Screening laboratory and other analyses show any of the following abnormal results:

• Aspartate transaminase (AST) or alanine transaminase (ALT) > 2 x the upper limit of the reference range;

• Total bilirubin = 3 mg/dL (51 µmol/L);

• Serum creatinine > 1.6 mg/dL (144 µmol/L)

• History of any drug or alcohol abuse in the past 2 years

• Receipt of other study product within 3 months of inclusion in this study

• Patients employed by the sponsor or in any relationship of dependence with the sponsor and/or investigator

• Staff at the study center

• Hypersensitivity to the active substance or to any of the excipients

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Crohn Disease
• Crohn's Disease
• Inflammation
• Mucosal Inflammation
• Mucositis

Intervention

Drug:
• ADALIMUMAB
Adalimumab at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly.
• Placebo
PLACEBO at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly

Locations

Country	Name	City	State
Belgium	Imeldaziekenhuis Bonheiden	Bonheiden
Belgium	Hospital Erasme Bruxelles	Bruxelles
Belgium	Hospital Saint Luc Bruxelles	Bruxelles
Belgium	Hospital University Gent	Gent
Belgium	Centre Hospitalier Universitaire de Liege	Liege
Belgium	Heiling Hartzieknhuis Roeselare	Roeselare
France	CHU Amiens - Hospital Nord	Amiens
France	CHU Tours - Hospital Trousseau	Chambray	Tours
France	Hospital Beaujon	Clichy
France	CHRU Lille - Hospital Claude Huriez	Lille
France	CHU Lyon Sud	Lyon
France	CHU Nantes	Nantes
France	Hospital Saint Louis	Paris
France	CHU Bordeaux - Hospital Haut-Leveque	Pessac	Bordeaux
France	CHRU Reims - Hospital Robert Debre	Reims
France	CHU Rouen - Hospital Charles Nicolle	Rouen
France	CH Saint Etienne - Hospital Nord	Saint Etienne
France	CHU Nancy - Hospital de Brabois Adultes	Vandoeuvre Les Nancy	Nancy
Spain	Hospital Germans Trias i Pujol	Badalona	Barcelona
Spain	Hospital Santa Creu i Sant Pau	Barcelona
Spain	Hospital Universitario Reina Sofia	Córdoba	Andalucía
Spain	Hospital Doctor Negrin	Las Palmas de Gran Canarias	Canarias
Spain	Hospital Gregorio Marañón	Madrid
Spain	Hospital Ramón y Cajal	Madrid
Spain	Hospital Universitario La Princesa	Madrid
Spain	Hospital de Manises	Manises	Valencia
Spain	Complejo Hospitalario Santiago de Compostela	Santiago de Compostela	A coruña
Spain	Hospital Virgen del Rocío	Sevilla
Spain	Hospital Clínico de Valencia	Valencia
Spain	Hospital Lozano Blesa	Zaragoza

Sponsors (3)

Lead Sponsor	Collaborator
Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa	Abbott, TFS Trial Form Support

Countries where clinical trial is conducted

Belgium,  France,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary efficacy endpoint is the rate of therapeutic failure up to week 48	The therapeutic failure is defined as any of following cases: CDAI > 220 with at least 70-point increase from baseline over two consecutive visits 12 weeks apart or CDAI > 300 at any time point during the study; need of any change in therapy for CD except the ones planned per protocol in each group of the study; need of surgery related to CD or of stricture endoscopic dilatation.	Every 12 weeks up to Week 48	No
Secondary	The rate of therapeutic failure (see the definition of primary endpoint) up to week 24		up to week 24	No
Secondary	Change in CDEIS from baseline to week 48	CDEIS = Crohn's Disease Endoscopic Index of Severity.	up to week 48	No
Secondary	The rate of mucosal healing (CDEIS=0) at week 48	CDEIS = Crohn's Disease Endoscopic Index of Severity	at week 48	No
Secondary	The rate of CDEIS remission (CDEIS<=3) at week 48	CDEIS = Crohn's Disease Endoscopic Index of Severity	at week 48	No
Secondary	The rate of CDEIS response, which is defined as a decrease of at least 4 points in CDEIS from baseline to week 48	CDEIS = Crohn's Disease Endoscopic Index of Severity	from baseline up to week 48	No
Secondary	Change in CDAI from baseline to week 12, 24, 36 and 48	CDAI = Crohn's Disease Activity Index.	from baseline to week 12, 24, 36 and 48	No
Secondary	Change in the global score based on IBDQ from baseline to week 12, 24, 36, and 48.	IBDQ = Inflammatory Bowel Disease Questionnaire.	from baseline to week 12, 24, 36, and 48.	No
Secondary	Area Under the Curve (AUC) over 48 weeks for CDAI		48 weeks	No
Secondary	The number of surgical interventions related to CD up to 24 and 48 weeks		up to 24 and 48 weeks	Yes
Secondary	The rate of hospital admissions related to the disease, to the treatment side effects or other causes up to weeks 24 or 48		up to weeks 24 or 48	Yes
Secondary	The rate of serious AEs between the two strategies up to 24 and 48 weeks		up to 24 and 48 weeks	Yes
Secondary	The rate of serious AEs requiring the cessation of the ongoing treatment between the two strategies up to 24 and 48 weeks.		up to 24 and 48 weeks	Yes
Secondary	The accuracy of calprotectin/hsCRP to predict therapeutic failure 12 weeks in advance		12 weeks	No
Secondary	The correlation between calprotectin, hsCRP and CDAI at any time points during the study.	Pearson Product-Moment Correlation will be used to evaluate correlations between calprotectin, hsCRP and CDAI at all scheduled visits.	48 weeks	No
Secondary	The correlation between calprotectin/hsCRP and CDEIS or mucosal healing at Baseline and Week 48.	Pearson Product-Moment Correlation will also be used to evaluate between calprotectin (and hsCRP) and CDEIS at Baseline and Week 48.	at Baseline and Week 48.	No
Secondary	Change in the scores based on WPAI from baseline to week 12, 24, 36 and 48	WPAI = Work Productivity and Activity Impairment Questionnaire	from baseline to week 12, 24, 36 and 48	No
Secondary	The change in calprotectin and hsCRP from baseline to week 12, 24, 36, and 48		from baseline to week 12, 24, 36, and 48	No